Advanced or Metastatic Colorectal Cancer

Oncology·MeSH: Colorectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

13 drugs in development·6 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
krazati	BRISTOL MYERS SQUIBB CO (BMY)

Phase 3(4)

Drug	Company
amivantamab	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
amivantamab sc	GH Research PLC (GHRS)
leucovorin calcium/levoleucovorin	GH Research PLC (GHRS)

Phase 2(5)

Drug	Company
FOLFIRI regimen	REGENXBIO Inc. (RGNX)
Ompenaclid	Merus N.V. (MRUS)
Ompenaclid	ENANTA PHARMACEUTICALS INC (ENTA)
Ompenaclid	REGENXBIO Inc. (RGNX)
Ompenaclid	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(1)

Drug	Company
amivantamab	GH Research PLC (GHRS)

Phase 1/Phase 2(2)

Drug	Company
amivantamab iv	GH Research PLC (GHRS)
leucovorin	GH Research PLC (GHRS)

BioSniper tracks 13 drugs in development for Advanced or Metastatic Colorectal Cancer across 6 companies.

There are 1 clinical trial targeting Advanced or Metastatic Colorectal Cancer tracked by BioSniper.

The estimated prevalence of Advanced or Metastatic Colorectal Cancer is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.